期刊
STEM CELL REVIEWS AND REPORTS
卷 13, 期 2, 页码 192-197出版社
SPRINGER
DOI: 10.1007/s12015-016-9716-y
关键词
Ischemic stroke; Stemcell therapy; Clinical trials; Translational research
资金
- VA Merit Review [I01 BX001407]
- [NIH R01NS071956]
- [NIH R01 NS090962]
- [NIH R21NS089851]
- [NIH R21 NS094087]
- [DOD W81XWH-11-1-0634]
Stem cell therapy for stroke has advanced from the laboratory to the clinic, but remains as an experimental treatment. Two lines of transplant regimens have emerged, namely the carly bird peripheral injections in subacute stroke patients and the late night direct intracerebral treatments in chronic stroke patients. Autologous bone marrow-derived stem cells, which only required minimal manipulations during graft cell preparation, gained fast-track entry into the clinic, while gene modified stem cells necessitated overcoming more stringent regulatory criteria before they were approved for clinical use. Safety of the stem cell therapy can be declared from these clinical trials, but efficacy warrants further investigations. Here, we offer insights into the translation of cell therapy from the laboratory to the clinic, in the hopes that highlighting the lessons we learned from this experience will guide the optimization of functional outcomes of future clinical trials of stem cell therapy for stroke.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据